Verastem down on duvelisib update at ASH

Verastem Inc. (NASDAQ:VSTM) fell $0.73 (17%) to $3.60 on Monday after reporting additional data from the Phase III DUO trial evaluating duvelisib (IPI-145) to treat relapsed or

Read the full 275 word article

User Sign In